GSK expands into Pakistan
This article was originally published in The Tan Sheet
Executive Summary
The U.K. firm gains more than 30 pharmaceutical brands, including antibiotics, vitamins and dermatology products, in its purchase of Bristol-Myers Squibb Pakistan, GlaxoSmithKline announces Dec. 22. The $36.5 million acquisition "reinforces our commitment to Pakistan" and broadens GSK's product portfolio, says Abbas Hussain, president of emerging markets for GSK. The company says BMSP's 2007 sales were about $19 million and Pakistan's total pharmaceutical market is $1.2 billion. GSK's goal is to introduce old products in new places and coordinate its Rx and OTC segments in emerging markets (1"The Tan Sheet" Oct. 27, 2008, p. 14)
You may also be interested in...
GSK Counts On China, Product Innovation To Boost Consumer Product Sales
GlaxoSmithKline recently launched its Sensodyne toothpaste line in China, its first new product there in more than 10 years
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.